Results of the phase Ib dose escalation study of MEN1611, a PI3K inhibitor, combined with trastuzumab (T) +/- fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC)

Simple item page
dc.conference.dateSEP 19-OCT 18, 2020
dc.conference.titleESMO Virtual Congress
dc.contributor.authorPiccart, M.
dc.contributor.authorRuiz Borrego, M.
dc.contributor.authorDuhoux, F.
dc.contributor.authorArkenau, H-T.
dc.contributor.authorDoger de Speville, B.
dc.contributor.authorWildiers, H.
dc.contributor.authorCampone, M.
dc.contributor.authorTosi, D.
dc.contributor.authorGarcia-Corbacho, J.
dc.contributor.authorJimenez, B.
dc.contributor.authorEscriva-de Romani, S.
dc.contributor.authorWardley, A. M.
dc.contributor.authorTassone, P.
dc.contributor.authorBoni, V.
dc.contributor.authorJerez, Y.
dc.contributor.authorAftimos, P. G.
dc.contributor.authorHennequin, A.
dc.contributor.authorAmair-Pinedo, F.
dc.contributor.authorPellacani, A. U. E.
dc.contributor.authorLaurent, D. O.
dc.contributor.authoraffiliation[Piccart, M.] Univ Libre Bruxelles, Inst Jules Bordet, Med Oncol Clin, Brussels, Belgium
dc.contributor.authoraffiliation[Aftimos, P. G.] Univ Libre Bruxelles, Inst Jules Bordet, Med Oncol Clin, Brussels, Belgium
dc.contributor.authoraffiliation[Ruiz Borrego, M.] Hosp Univ Virgen del Rocio, Med Oncol, Seville, Spain
dc.contributor.authoraffiliation[Duhoux, F.] Catholic Univ Louvain, Clin Univ St Luc, Inst Roi Albert II, Woluwe St Lambert, Belgium
dc.contributor.authoraffiliation[Arkenau, H-T.] Sarah Cannon Res Inst, Drug Dev Program, London, England
dc.contributor.authoraffiliation[Doger de Speville, B.] Fdn Jimenez Diaz Univ Hosp, START Madrid, Madrid, Spain
dc.contributor.authoraffiliation[Wildiers, H.] Univ Hosp Leuven, Dept Gen Med Oncol, Leuven, Belgium
dc.contributor.authoraffiliation[Campone, M.] ICO Inst Cancerol Ouest Rene Gauducheau, Med Oncol Serv, St Herblain, France
dc.contributor.authoraffiliation[Tosi, D.] Montpellier Univ, Inst Canc Montpellier, Dept Med Oncol, Inserm,U1194, Montpellier, France
dc.contributor.authoraffiliation[Garcia-Corbacho, J.] Hosp Clin Barcelona, Clin Trials Unit Haematol & Oncol Dis, Barcelona, Spain
dc.contributor.authoraffiliation[Garcia-Corbacho, J.] Hosp Clin Barcelona, Early Phase CCTT, Barcelona, Spain
dc.contributor.authoraffiliation[Jimenez, B.] Hosp Clin Univ Virgen de la Victoria, Med Oncol, Malaga, Spain
dc.contributor.authoraffiliation[Escriva-de Romani, S.] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Barcelona, Spain
dc.contributor.authoraffiliation[Wardley, A. M.] Univ Manchester, NIHR Manchester Clin Res Facil Christie, Fac Biol Med & Hlth, Manchester, Lancs, England
dc.contributor.authoraffiliation[Wardley, A. M.] Univ Manchester, Div Canc Sci, Sch Med Sci, Fac Biol Med & Hlth, Manchester, Lancs, England
dc.contributor.authoraffiliation[Tassone, P.] Magna Graecia Univ Catanzaro, Dept Expt & Clin Med, AO Policlin Mater Domini Univ, Catanzaro, Italy
dc.contributor.authoraffiliation[Boni, V.] HM Hosp Sanchinarro, START Madrid CIOCC, Madrid, Spain
dc.contributor.authoraffiliation[Jerez, Y.] Hosp Gen Univ Gregorio Maranon, Dept Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Hennequin, A.] Ctr Georges Francois Leclerc, Med Oncol, Dijon, France
dc.contributor.authoraffiliation[Amair-Pinedo, F.] Menarini Ind Farmaceut Riunite IFR Srl, R&D, Florence, Italy
dc.contributor.authoraffiliation[Laurent, D. O.] Berlin Chem AG, Translat Med Oncol, Berlin, Germany
dc.contributor.funderMenarini Ricerche S.p.A.
dc.date.accessioned2025-01-07T15:23:25Z
dc.date.available2025-01-07T15:23:25Z
dc.date.issued2020-09-01
dc.identifier.doi10.1016/j.annonc.2020.08.449
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttp://www.annalsofoncology.org/article/S0923753420404454/pdf
dc.identifier.urihttps://hdl.handle.net/10668/27097
dc.identifier.wosID573469100347
dc.issue.number4
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Virgen de la Victoria
dc.organizationSAS - Hospital Universitario Virgen del Rocío
dc.page.numberS386-S386
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.titleResults of the phase Ib dose escalation study of MEN1611, a PI3K inhibitor, combined with trastuzumab (T) +/- fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC)
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number31
dc.wostypeMeeting Abstract

Files

Collections

SAS - Hospital Universitario Virgen de la Victoria
SAS - Hospital Universitario Virgen del Rocío

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía